NEJM Volume 394, Issue 9: February 26, 2026 – Medical Research
New research published today, , in the New England Journal of Medicine details promising advancements in the treatment of HER2-positive metastatic breast cancer. The study investigates the efficacy of combining trastuzumab deruxtecan with pertuzumab, offering a potential new avenue for patients who have exhausted other treatment options.
Understanding HER2-Positive Breast Cancer
Breast cancer is not a single disease, but rather a collection of diseases with different characteristics and behaviors. HER2-positive breast cancer, accounting for approximately 20% of all breast cancers, is characterized by a high level of expression of the human epidermal growth factor receptor 2 (HER2) protein. This overexpression promotes the growth and spread of cancer cells. While significant progress has been made in treating HER2-positive breast cancer with targeted therapies like trastuzumab and pertuzumab, many patients eventually develop resistance, leading to disease progression.
The Study: Trastuzumab Deruxtecan and Pertuzumab
The recent study focused on patients with HER2-positive metastatic breast cancer who had previously received at least two prior anti-HER2-based regimens. Researchers evaluated the combination of trastuzumab deruxtecan – a HER2-directed antibody drug conjugate – and pertuzumab, another HER2-targeted therapy. The goal was to determine if this combination could overcome resistance and improve outcomes for these patients.
Trastuzumab deruxtecan delivers a potent chemotherapy drug directly to cancer cells expressing HER2, minimizing damage to healthy tissues. Pertuzumab works by preventing HER2 from pairing with other HER receptors, thereby inhibiting cancer cell growth. Combining these two agents aims to provide a more comprehensive attack on HER2-positive cancer cells.
Key Findings and Implications
The research, published in Volume 394, Issue 9 of the New England Journal of Medicine, demonstrates encouraging results. While specific data points are available in the full publication, the study suggests that the combination therapy shows clinical activity in patients with heavily pretreated HER2-positive metastatic breast cancer. This is particularly significant as treatment options become limited for patients who have progressed on prior therapies.
The study’s findings underscore the importance of continued research into novel therapeutic strategies for HER2-positive breast cancer. The development of antibody-drug conjugates like trastuzumab deruxtecan represents a significant step forward in targeted cancer therapy, allowing for more precise and effective treatment delivery.
What Which means for Patients
For patients with HER2-positive metastatic breast cancer, this research offers a glimmer of hope. The combination of trastuzumab deruxtecan and pertuzumab may provide a valuable treatment option for those who have not responded to other therapies. However, it’s crucial to remember that this is a complex disease, and treatment decisions should be made in consultation with a qualified oncologist.
, as with any cancer treatment, this combination therapy is likely to have side effects. Patients should discuss the potential risks and benefits with their healthcare team to determine if this treatment is appropriate for their individual circumstances. Further research is needed to fully understand the long-term effects and optimal use of this combination.
The Ongoing Commitment of the New England Journal of Medicine
The publication of this research in the New England Journal of Medicine highlights the journal’s dedication to disseminating cutting-edge medical research to the medical community. The February 26, 2026 issue, Volume 394, Issue 9, features this study alongside other important contributions to the field of medicine, reinforcing the journal’s role as a leading source of medical knowledge.
The journal’s commitment to rigorous peer review and evidence-based reporting ensures that healthcare professionals have access to the most reliable and up-to-date information available, ultimately benefiting patients worldwide. The ongoing investigation into treatments like trastuzumab deruxtecan and pertuzumab exemplifies the continuous pursuit of improved outcomes for individuals battling HER2-positive metastatic breast cancer.
Further studies are planned to investigate the optimal dosage and sequencing of these therapies, as well as to identify biomarkers that may predict which patients are most likely to benefit from this combination. The hope is that these efforts will lead to even more personalized and effective treatment strategies for HER2-positive breast cancer in the future.